The influence of rosiglitazone on quality of life and prognosis of early-stage glottic laryngeal carcinoma patients

Abstract

Abstract We aimed to clarify influence of rosiglitazone on quality of life and prognosis of early-stage glottic laryngeal carcinoma patients. The control group was treated with low-temperature plasma radiofrequency ablation, and the observation group was additionally given rosiglitazone, 4 mg, 2 times/d. Treatment continued for 6 months. After treatment, the fundamental frequency perturbation and amplitude perturbation presented depletion and the harmonic-to-noise ratio presented increase in observation group relative to control group. Total effective rate was 80.31% in observation group and 77.14% in control group (P > 0.05). Peripheral blood immune makers CD3+, CD4+, CD4+/CD8 + and NK cell levels in observation group presented elevation relative to control group, while CD8 + level presented depletion. The incidence rates of adverse reactions were lower in observation group than control group. The median survival time in control group was 33 months, and that in observation group was 47 months (P < 0.05). The 5-year survival rate was 77.14% (27/35) in observation group and 54.29% (19/35) in control group (P < 0.05). In conclusion, rosiglitazone can prolong the survival of early-stage glottic laryngeal carcinoma patients, improve their immune function and quality of life, and reduce adverse reactions during treatment, which is an ideal treatment plan.